For example, EGFR and HER-2 mutations, and the fusion of ALK, ROS1, RET, MET could define NSCLC subsets with minimal benefit from ICIs, despite of high PD-L1 expression (35). This evidence concerns the gene EGFR and non-small cell lung carcinoma.